Table 3.
Comparison of clinical characteristics of patients who initially underwent RP versus those who underwent RP after termination of AS.
| Initially underwent RP | RP after termination of AS | P | |
|---|---|---|---|
| No. of patients | 58 | 20 | |
| Age (y) | 67.0 ± 5.7 | 66.0 ± 4.5 | 0.571 |
| Charlson comorbidity index (≥2) | 11 (19.00) | 3 (15.0) | 0.723 |
| Family history | 4 (6.9) | 2 (10.0) | 0.655 |
| PSA (ng/mL) | 5.7 ± 1.8 | 6.4 ± 3.1 | 0.615 |
| Prostate volume (cc) | 41.6 ± 16.6 | 40.3 ± 11.7 | 0.864 |
| PSA density (ng/mL/cc) | 0.15 ± 0.07 | 0.17 ± 0.08 | 0.672 |
| Gleason Grade group 2 | 12 (20.7) | 3 (15.0) | 0.580 |
| Clinical stage (cT2) | 10 (17.2) | 5 (25.0) | 0.452 |
| No. of positive biopsy cores | 1.4 ± 0.5 | 1.1 ± 0.5 | 0.026 |
| % of maximum core involvement (≤50) | 17.4 ± 14.0 | 11.7 ± 15.6 | 0.007 |
| Incidental PCa after TURP | 0 (0.0) | 4 (20.0) | 0.001 |
| % of positive biopsy chips | – | 7.6 ± 11.6 | |
| Follow-up duration (mo) | 47.4 ± 28.7 | 51.2 ± 24.8 | 0.563 |
| AS adherence duration (mo) | 23.7 ± 15.7 | ||
| Risk stratification (FI) | 8 (13.8) | 6 (30.0) | 0.035 |
| Pathologic stage (pT3) | 2 (3.4) | 3 (15.0) | 0.183 |
| pathologic Gleason Grade group 2 | 24 (41.4) | 9 (45.0) | 0.660 |
| Tumor volume (cc) | 1.0 ± 1.0 | 1.2 ± 1.4 | 0.362 |
| No. of significant PCa | 31.0 (53.4) | 15 (75.0) | 0.093 |
| No. of upgrading | 2 (3.4) | 3 (15.0) | 0.303 |
| No. of upstaging | 16 (27.6) | 8 (40.0) | 0.071 |
| No. of upgrading or upstaging | 17 (29.3) | 10 (50.0) | 0.096 |
Data are n (%) or mean ± standard deviation.
AS, active surveillance; FI, favorable intermediate; PCa, prostate cancer; PSA, prostate-specific antigen; RP, radical prostatectomy; TURP, transurethral resection of prostate.